Approval (2017) FDA News Release: FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (March 08, 2024) Once-Weekly Semaglutide for Weight Management: A Clinical Review - PMC Once-Weekly Semaglutide in Adults With Overweight or Obesity (March 2021) Oral Semaglutide Versus Subcutaneous Liraglutide And Placebo In Type 2 Diabetes (PIONEER 4): A Randomised, Double-Blind, Phase 3a Trial Efficacy And Safety Of Once-Weekly Semaglutide 20 Mg Versus 10 Mg In Patients With Type 2 Diabetes (Sustain Forte): A Double-Blind, Randomised, Phase 3b Trial (September 2021) Rybelsus Dosing Schedule Ozempic Dosing Schedule Wegovy Dosing Schedule Semaglutide (February 11, 2024) Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A1C and Weight in Patients with Type 2 Diabetes (November 5, 2024) Daily Glucose Profiles After Switching from Injectable to Oral Semaglutide in Patients with Type 2 Diabetes Mellitus (May 2023)
Zimprich A, Biskup S, Leitner P, et al
Accordingly, the primary cardiovascular risk assessment of tirzepatide comprised the interim analysis, and the subsequent analyses using the final dataset after the completion of SURPASS-4 and SURPASS J-mono were conducted using a nominal significance level of 0.05 (95% CI)
High levels of bad cholesterol (LDL) and triglycerides, along with low levels of good cholesterol (HDL), increase the risk of heart disease
